MVMD Selactosol™ Interview
Mike Farber and Steve Darling from Proactive Investor discussed MVMD's new water-solubilized selamectin breakthrough
By Dennis H.
- Interview Overview: Mike and Steve Darling from Proactive Investor discussed MVMD's new water-solubilized selamectin breakthrough in a short but insightful interview.
- Potential Applications: The implications of Selactosol™, especially against tuberculosis (TB), are profound and represent just the beginning of the broader applications being pursued.
- Targeted Impact: The technology at MVMD is focused on making significant impacts on global health challenges, such as TB, which affects a quarter of the world's population.
- Interview Overview: Mike Farber and Steve Darling from Proactive Investor discussed MVMD's new water-solubilized selamectin breakthrough in a short but insightful interview.
- Potential Applications: The implications of Selactosol™, especially against tuberculosis (TB), are profound and represent just the beginning of the broader applications being pursued.
- Targeted Impact: The technology at MVMD is focused on making significant impacts on global health challenges, such as TB, which affects a quarter of the world's population.
Mike and I had a chance to run through our media release this afternoon with Steve Darling from Proactive Investor. It is short interview, but a great overview of the magnitude of MVMD’s new water solubilized selamectin breakthrough.
Understanding the potential implications of how Selactosol™ could be applied against tuberculosis is fascinating and it is just the tip of the iceberg to the broad applications we are pursuing. TB is the number one infectious cause of death worldwide and impacts a quarter of the world’s population. This is the type of impact that our technology at MVMD is squarely focused on!